Delta-9-Tetrahydrocannabinol alleviates chemotherapy-induced weight loss but not colitis
| Journal | Journal of cannabis research |
| Study Type | Clinical Study |
| Population | Human participants |
Chemotherapy-induced gastrointestinal mucositis affects up to 80% of cancer patients, causing significant morbidity and treatment delays. This preclinical study examines whether THC could offer therapeutic benefit for this challenging clinical problem where current interventions remain limited.
This mouse study evaluated oral THC oil (10 mg/kg or 20 mg/kg daily) against doxorubicin-induced mucositis and DSS-induced colitis using C57BL6 mice. THC demonstrated protective effects against chemotherapy-induced weight loss but showed no benefit for inflammatory colitis. The study measured standard endpoints including weight changes, intestinal length, histopathology, and gene expression markers. While promising for mucositis-related weight preservation, the lack of anti-inflammatory effect in the colitis model suggests mechanism-specific activity rather than broad gastrointestinal protection.
“This adds to emerging preclinical evidence that THC may help preserve weight during chemotherapy, but I’m cautious about extrapolating anti-inflammatory benefits to human IBD. The differential effects between mucositis and colitis models suggest we need more nuanced understanding of cannabinoid mechanisms in different GI conditions.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Can THC help prevent weight loss during chemotherapy?
This preclinical study found that THC oil at 10-20 mg/kg doses alleviated doxorubicin-induced weight loss in mice. However, this is early animal research and human clinical trials are needed to determine safety and efficacy in cancer patients undergoing chemotherapy.
Is THC effective for treating inflammatory bowel disease symptoms?
This study showed THC did not significantly affect DSS-induced colitis in mice, suggesting limited anti-inflammatory effects in this IBD model. The findings contradict some previous animal studies and indicate THC may not be universally effective for all types of intestinal inflammation.
What doses of THC were tested for gastrointestinal conditions?
Researchers tested daily oral doses of 10 mg/kg and 20 mg/kg THC oil in mice. These are preclinical doses that cannot be directly translated to human dosing without proper clinical trials and safety studies.
Does this research support using medical cannabis for chemotherapy side effects?
The study provides preliminary evidence that THC may help with chemotherapy-induced weight loss but shows mixed results for gastrointestinal inflammation. More human clinical research is needed before making treatment recommendations for cancer patients.
Are there safety concerns with using THC for gastrointestinal problems?
This animal study did not report significant safety issues, but human safety data is limited. Patients should consult healthcare providers before using THC products, as they may interact with medications and cause psychoactive effects.
